Coronavirus latest update: Drugs Controller General of India (DCGI) Dr. VG Somani on Tuesday allowed the Serum Institute of India to resume clinical trials of the Oxford COVID-19 vaccine candidate in the country, while canceling its earlier order suspending any new recruitment for it. gave. Phase two and three tests.
DCGI, however, carries certain conditions such as extra care during screening, providing informed consent for adverse events and additional information in close monitoring during the follow-up of the study, followed by the Serum Institute of India (SII) Have to go .
On 11 September DCGI directed Serum Institute of India to postpone any new trials of the Oxford COVID-19 vaccine to postpone any new recruitment in the second phase until further orders in the backdrop of pharma giant AstraZeneca. Do it, because clinical trials are taking place in other countries. “An unexplained disease” in one participant in the study.